These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32914327)

  • 41. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
    Lucas T; Astorga R;
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The utility of gastrojejunostomy in secondary cytoreduction and palliation of proximal intestinal obstruction in recurrent ovarian cancer.
    Winter WE; McBroom JW; Carlson JW; Rose GS; Elkas JC
    Gynecol Oncol; 2003 Oct; 91(1):261-4. PubMed ID: 14529692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.
    Wymenga AN; Eriksson B; Salmela PI; Jacobsen MB; Van Cutsem EJ; Fiasse RH; Välimäki MJ; Renstrup J; de Vries EG; Oberg KE
    J Clin Oncol; 1999 Apr; 17(4):1111. PubMed ID: 10561168
    [TBL] [Abstract][Full Text] [Related]  

  • 44. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
    Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
    Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Hepatic encephalopathy after injection of lanreotide, a somatostatin analog].
    Robin E; Lebrec D; Hammel P; Bernades P; Ruszniewski P
    Gastroenterol Clin Biol; 1996; 20(11):1014-6. PubMed ID: 9119171
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Postpyloric decompression tube placement through a gastrostomy for malignant bowel obstruction.
    Kurita Y; Koide T; Watanabe S; Ogawa T; Sekino Y; Iida H; Nonaka T; Kusakabe A; Gotoh E; Maeda S; Nakajima A; Inamori M
    BMC Res Notes; 2013 Jun; 6():217. PubMed ID: 23731859
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Percutaneous endoscopic gastrostomy (PEG) in upper gastrointestinal tract occlusion in gynecologic oncology].
    Campagnutta E; Cannizzaro R; De Cicco M; De Piero G; Giorda G; Sopracordevole F; Parin A; Scarabelli C
    Minerva Ginecol; 1998; 50(7-8):305-11. PubMed ID: 9808954
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ultrasound-assisted percutaneous endoscopic gastrostomy in a patient with advanced ovarian carcinoma and recurrent intestinal obstruction.
    Vargo JJ; Germain MM; Swenson JA; Harrison CR
    Am J Gastroenterol; 1993 Nov; 88(11):1946-8. PubMed ID: 8237947
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term lanreotide treatment in six patients with congenital hyperinsulinism.
    Kühnen P; Marquard J; Ernert A; Meissner T; Raile K; Wannenmacher G; Blankenstein O
    Horm Res Paediatr; 2012; 78(2):106-12. PubMed ID: 22907123
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
    Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
    J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of a safe site for percutaneous endoscopic gastrostomy placement in patients with marked bowel distension: may octreotide have a role?
    Sartori S; Trevisani L; Nielsen I; Tassinari D; Righini E
    Endoscopy; 1994 Oct; 26(8):710-1. PubMed ID: 7859687
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical utility of lanreotide Autogel
    Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
    Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
    Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
    Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medical management of intestinal obstruction in terminal care.
    Frank C
    Can Fam Physician; 1997 Feb; 43():259-65. PubMed ID: 9040913
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
    Meijer E; Visser FW; van Aerts RMM; Blijdorp CJ; Casteleijn NF; D'Agnolo HMA; Dekker SEI; Drenth JPH; de Fijter JW; van Gastel MDA; Gevers TJ; Lantinga MA; Losekoot M; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Wetzels JF; Zietse R; Gansevoort RT;
    JAMA; 2018 Nov; 320(19):2010-2019. PubMed ID: 30422235
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
    Capdevila J; Sevilla I; Alonso V; Antón Aparicio L; Jiménez Fonseca P; Grande E; Reina JJ; Manzano JL; Alonso Lájara JD; Barriuso J; Castellano D; Medina J; López C; Segura Á; Carrera S; Crespo G; Fuster J; Munarriz J; García Alfonso P
    BMC Cancer; 2015 Jul; 15():495. PubMed ID: 26138480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term treatment of thyrotropin-secreting microadenoma with lanreotide and cabergoline.
    Pichler R; Maschek W
    Eur J Endocrinol; 2001 Feb; 144(2):179-80. PubMed ID: 11182755
    [No Abstract]   [Full Text] [Related]  

  • 58. Intestinal obstruction from advanced gastrointestinal or gynecological cancer.
    Feuer D; Broadley KE; Shepherd JH; Barton DP
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):394-5. PubMed ID: 10985902
    [No Abstract]   [Full Text] [Related]  

  • 59. Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series.
    Caceres A; Zhou Q; Iasonos A; Gerdes H; Chi DS; Barakat RR
    Gynecol Oncol; 2008 Mar; 108(3):482-5. PubMed ID: 18190953
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lanreotide in the management of small bowel angioectasias: seven-year data from a tertiary centre.
    Chetcuti Zammit S; Sanders DS; Sidhu R
    Scand J Gastroenterol; 2017 Sep; 52(9):962-968. PubMed ID: 28506132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.